Cell-based therapy in lung regenerative medicine.
Cell-based therapy in lung regenerative medicine.
复制标题
DOI：
10.1186/2050-490x-2-7
复制
发表时间：
2014-12
影响因子：
2
通讯作者：
Jia Z
中科院分区：
文献类型：
--
作者：
Yang J;Jia Z
慢性肺病正在成为全世界死亡的主要原因。对这些患者有效的治疗方法很少，预防疾病恶化甚至逆转疾病进展的选择较少。在过去的十年中，使用干细胞再生肺组织的基于细胞的疗法在各种不同肺部疾病的动物模型中经历了快速增长。这种新方法为治疗几种毁灭性和不可治愈的肺部疾病提供了巨大的希望，包括肺气肿，特发性肺纤维化，肺动脉高压和急性呼吸窘迫综合征。在这篇综述中，我们提供了一个简明的总结目前知识的属性内源性肺上皮干/祖细胞（EpiSPCs），间充质干细胞（MSCs）和内皮祖细胞（EPCs）在动物模型和翻译研究。我们还描述了组织生物工程在肺再生医学中的前景和挑战。MSC在IPF和慢性阻塞性肺疾病（COPD）中的治疗潜力进一步讨论。
Chronic lung diseases are becoming a leading cause of death worldwide. There are few effective treatments for those patients and less choices to prevent the exacerbation or even reverse the progress of the diseases. Over the past decade, cell-based therapies using stem cells to regenerate lung tissue have experienced a rapid growth in a variety of animal models for distinct lung diseases. This novel approach offers great promise for the treatment of several devastating and incurable lung diseases, including emphysema, idiopathic pulmonary fibrosis, pulmonary hypertension, and the acute respiratory distress syndrome. In this review, we provide a concise summary of the current knowledge on the attributes of endogenous lung epithelial stem/progenitor cells (EpiSPCs), mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) in both animal models and translational studies. We also describe the promise and challenges of tissue bioengineering in lung regenerative medicine. The therapeutic potential of MSCs is further discussed in IPF and chronic obstructive pulmonary diseases (COPD).